靶向药物阿帕替尼辅助三维适形调强放疗治疗老年非小细胞肺癌患者的临床效果

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (0 KB) HTML (37 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of targeted drug Apatinib assisted three-dimensional conformal intensity-modulated radiotherapy in the treatment of elderly patients with non-small cell lung cancer.Methods A total of 80 cases of elderly patients with non-small cell lung cancer who were treated in Yancheng Second People′s Hospital from January 2017 to December 2019 were selected as the subjects，and they were divided into the observation group and the control group using the random number table method，40 cases in each group.The control group was given three-dimensional conformal intensity-modulated radiotherapy，the observation group was given Apatinib on the basis of the control group，the total clinical effective rate，serum carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF) levels before and after treatment and incidence of adverse reactions of the two groups were compared.Results One month after the end of the treatment，the total clinical effective rate of the observation group was 62.5%，which was higher than that of the control group (45.0%)，the difference was statistically significant (P＜0.05).After treatment，compared with before treatment，the serum CEA and VEGF levels of the two groups decreased，and the serum CEA and VEGF levels of the observation group were lower than those of the control group，the differences were statistically significant (P＜0.05).The main adverse reactions of the two groups were hypertension，hemorrhage，gastrointestinal reaction，hemoglobin reduction，leucopenia and liver and kidney dysfunction.The total incidence rate of adverse reactions in the observation group was 17.5%，which was lower than that in the control group (37.5%)，the difference was statistically significant (P＜0.05).Conclusion The effect of Apatinib in the combination with three-dimensional conformal intensity-modulated radiotherapy in the treatment of elderly patients with non-small cell lung cancer is definite，the serum CEA and VEGF levels are significantly improved，the adverse reactions are few，and the therapeutic effect is significant，which is worthy of clinical application.

Key words： Apatinib Three-dimensional conformal intensity-modulated radiotherapy Elderly with non-small cell lung cancer Clinical effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WU Xiao-ling
	YANG Yu
	MA Gao-jian
	MA Qing-mei

Cite this article:

WU Xiao-ling,YANG Yu,MA Gao-jian, et al. Clinical effect of targeted drug Apatinib assisted three-dimensional conformal intensity-modulated radiotherapy in the treatment of elderly patients with non-small cell lung cancer[J]. 中国当代医药, 2020, 27(33): 9-12.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I33/9

[1]	李修炜.TC 化疗方案联合三维适形调强放疗治疗非小细胞肺癌的效果分析[J].河南医学研究，2018，27（6）：1049-1050.
[2]	张振坤，王筱芳，吴福勇.阿帕替尼靶向治疗联合调强放疗在胃癌患者中的应用及对治疗依从性影响[J].新疆医科大学学报，2018，41（8）：971-974.
[3]	Zhang T，Zhao YT，Wang Z，et al.Efficacy and Safety of Intensity-Modulated Radiotherapy Following Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma[J].Medicine（Baltimore），2016，95（21）：e3789.
[4]	吴阳，李亮，余红民.同期推量调强放疗与序贯推量调强放疗治疗老年局晚期非小细胞肺癌的效果比较[J].中国当代医药，2015，22（26）：42-45.
[5]	王学敏，张维红，杜伟娇，等.阿帕替尼用于一线治疗进展后晚期非鳞非小细胞肺癌的疗效和生存分析[J].中国肺癌杂志，2017，20（11）：761-768.
[6]	Zhang H.Apatinib for molecular target therapy in tumor[J].Drug Des Devel Ther，2015，9：6075-6081.
[7]	王荣，易敏，杨世荣，等.周剂量多西他赛联合三维适形放疗治疗老年非小细胞肺癌的临床疗效[J].中国老年学杂志，2015，35（4）：1081-1082.
[8]	潘振华，单娟，郭小奇，等.阿帕替尼联合调强适形放疗治疗Ⅲ～Ⅳ期非小细胞肺癌的疗效及安全性研究[J].癌症进展，2018，16（15）：1868-1871.
[9]	Isohashi F，Mabuchi S，Yoshioa Y，et al.Postoperative wholepelvic intensity modulated radiation therapy in surgically treated cervical cancer patients with adverse risk factors[J].Int J Radiat Oncol Biol Phys，2016，96（2）：312-313.
[10]	王直，陈其亮，李军孝，等.长春瑞滨联合顺铂化疗方案对非小细胞肺癌患者凝血功能的动态影响及意义[J].现代肿瘤医学，2016，24（10）：1545-1549.
[11]	曹恒，王静，纪媛媛，等.甲磺酸阿帕替尼治疗晚期非小细胞肺癌临床观察[J].中华肿瘤防治杂志，2017，24（7）：468-471.
[12]	刘国慧，王春波，鄂明艳.放疗联合阿帕替尼治疗非小细胞肺癌的机制及研究前景[J].中国肺癌杂志，2017，20（12）：847-851.
[13]	张捷，刘骅，沈志勇.卡培他滨加奥沙利铂同期化疗与三维适形放疗联合治疗术后复发直肠癌的临床疗效[J].癌症进展，2016，14（3）：277-279.
[14]	Horn L，Reck M，Spigel DR.The future of immunotherapyin the treatment of small cell lung cancer[J].Oncologist，2016，21（8）：910-921.
[15]	曲范杰，于韦韦，张捷.阿帕替尼联合化疗治疗晚期小细胞肺癌1例报告及文献复习[J].中国肿瘤生物治疗杂志，2017，24（8）：923-925.
[16]	张智显，顾后，林劼，等.阿帕替尼联合替莫唑安序贯全脑放疗二线治疗小细胞肺癌脑转移[J].昆明医科大学学报，2019，40（8）：97-101.
[17]	陈育标.TP 方案诱导化疗联合三维适形放疗同期化疗治疗非小细胞肺癌的临床研究[J].临床和实验医学杂志，2016，15（12）：1161-1163.
[18]	Ding L，Li QJ，You KY，et al.The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature[J].Medicine（Baltimore），2016，95（20）：e3598.
[19]	李发祥.阿帕替尼联合GP 方案治疗晚期非小细胞肺癌的疗效及安全性[J].实用癌症杂志，2019，34（6）：952-955.
[20]	蔡鹏.同步放化疗与放疗同步联合阿帕替尼治疗Ⅲ期不能手术非小细胞肺癌的临床疗效比较[J].实用癌症杂志2018，33（3）：454-457.